To examine the patterns of utilization of radiation therapy, chemotherapy, surgery, and hospice at the end-of-life care for patients diagnosed with metastatic melanoma.
T he incidence rate of malignant melanoma has been increasing since the 1950s. 1, 2 The overall growth rate was 45% from 1992 to 2004, resulting in an annual growth rate of 3.1%, faster than that for any other cancer. 3 Melanoma accounts for fewer than 5% of all skin cancer cases but for over 75% of skin cancer deaths. 4 The intensity of care provided to this rapidly growing group of patients has been studied less than that for other malignant tumors.
Several previous studies have examined the use of care at the end of life among cancer patients using a variety of data sources, and these studies have shown trends of overuse of aggressive care for cancer patients close to death. 5, 6 There have also been increasing trends in hospice enrollment over the years for cancer patients. 7 We sought to examine trends in the utilization of radiation therapy, surgery, chemotherapy, and hospice among patients with metastatic melanoma. We analyzed the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare data to assess the patterns of care and the influence of clinical and demographic factors on trends in utilization of various aspects of the end-of-life care for elderly patients dying of metastatic melanoma. We tested 2 hypotheses in this study: (1) that patients who enroll in hospice use significantly less surgery, chemotherapy, and radiotherapy than those who do not and (2) that the percentage of patients who use short-term hospice ( r3 d) is larger than the percentage of patients who use long-term hospice (Z4 d) among patients with metastatic melanoma.
METHODS
We used data from the SEER-Medicare database that links Medicare beneficiaries and their Medicare claims files with patients in the SEER tumor registries. 8 This National Cancer Institute supported data set covers 17 geographic areas in the United States, an estimated 28% of the US population. Its linked Medicare database includes biennially updated medical claims for 97% of US citizens aged 65 years or above. 9 To obtain treatment information, we used the encrypted identifier in the Patients Entitlement and Diagnosis Summary File linked with all available Medicare claims files, including inpatient care, skilled nursing facility care, home health care, hospice care, physician visits, outpatient care, and durable equipment. All data were de-identified such that no protected health information can be linked to individual patients. The Institutional Review Boards from the University of Texas MD Anderson Cancer Center and the University of Texas Health Science Center in Houston had exempted this study. We identified 816 Medicare beneficiaries 65 years of age or above who were diagnosed with pathologically confirmed stage IV malignant melanoma between January 1, 2000 and December 31, 2007, and who used the SEER variable HSTST (historic stage = "distant"). Inclusion criteria used to identify the cohort included matching dates of death in the SEER data set and the Medicare data set, a diagnosis that was not derived from an autopsy report or a death certificate, continuous coverage part A and part B enrollment in Medicare from the diagnosis date until death, and no managed-care organization enrollment after the diagnosis date.
Dependent Variables
We used International Classification of Diseases, 9th edition, procedure codes, and Current Procedural Terminology (CPT) codes to identify chemotherapy, surgery, and radiation therapy. Chemotherapy CPT codes used were 9925, 96400-96599, J9000-J9999, J8501-J8999, and Q0081-Q0085. Surgery CPT codes used were 21011-21016, 21555 Radiation therapy CPT codes analyzed were 61796-61800, 63620-63621, 77400-77416, 77418, G0174, 0197T, 77371-77373, 77435, 77520-77525, G0173, G0251, G0338, G0339, and G0340. We identified the utilization of these modalities according to periods at the end of life relative to death. The date of death was used as an index to define 4 periods of observation: the last week before death, the last month before death, the last 3 months before death, and the last 6 months before death. The frequency of end-of-life care was measured in each period.
Independent Variables
The initial selection of independent variables was based on the review of available major determinants of medical care utilization from the Andersen health service utilization model. 10 The year of death, the age at diagnosis, the sex, the marital status, the median household income for the region of residence, education, the geographic region of residence, the comorbidity score, and days of hospice use (categorized as no hospice, hospice 1 to 3 d, and hospice 4 + d) were the selected covariates for multiple logistic regression models. Age was categorized as 65 to 74 years and 75 years or above. Marital status was categorized as married or other. The Charlson comorbidity score was calculated from an algorithm developed by Klabunde et al 11, 12 using Medicare inpatient and outpatient claims within the 12-month window before death. We used neighborhood income and education variables at the level of zip code as provided in the SEER-Medicare database. The use of hospice care was identified on the basis of any hospice admission and/or service date after advanced metastatic melanoma diagnosis date in the SEER-Medicare hospice claims file. The SEER-Medicare database was linked to the Area Resource File 13 through Health Service Area codes provided in the databases to count the number of Medicare-certified hospice facilities available within each patient's Health Service Area.
Statistical Analysis
We conducted a univariate analysis with a w 2 test, comparing the demographic and clinical characteristics between patients who received various treatments and hospice care and those who did not. We used the Cochran-Armitage test to evaluate the time trends for categorical variables. We used multivariate logistic regression to evaluate the associations between demographic and clinical explanatory variables and the use of hospice care and receipt of chemotherapy, surgery, or radiation therapy. We used forward selection (P < 0.05) to eliminate insignificant explanatory variables in regression modeling. We then investigated possible interaction terms by multivariate logistic regression modeling. Statistical analysis was conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC).
RESULTS

Utilization of Chemotherapy, Surgery, and Radiation Therapy
The characteristics of the study cohort are listed in Table 1 , stratified by duration of hospice use. In the total cohort, 256 patients (31.3%) received chemotherapy, 199 (24.4%) received surgery, and 320 (39.2%) received radiation therapy (the year-by-year analysis is shown in Fig. 1 ). The proportion of patients receiving chemotherapy fluctuated from 28% in 2000 to 38% in 2004 and back to 27% in 2007 (the Cochran-Armitage trend test, P = 0.43). Radiation therapy use was 35% in 2000, 46% in 2004 and 2005, and then 38% in 2007 (P = 0.46). Figure 1B demonstrates the increasing use of surgery over the study period, from 13% in 2000 to 30% in 2007 (P = 0.03).
A multivariate logistic regression of the factors associated with receiving chemotherapy is shown in Table 2 . The factors that were consistently associated with a lower likelihood of receiving chemotherapy were an older age and not being married (all P < 0.05). For the multivariate analysis of factors predicting the utilization of surgery, 2 characteristics were independently associated with higher odds of receiving surgery, as shown in Table 2 : the year of death and the SEER region. Patients living in the northeast region and the southern region had lower odds of receiving surgery than patients who lived in the West/Hawaii region; however, the differences in the odds were not significant for the midwest region. The odds of receiving surgery increased over the years from 2001 to 2007. An older age and not being married were also significantly associated with a lower utilization of radiation therapy. In the multivariate analysis of factors associated with receiving radiation therapy, patients who lived in the SEER southern region had lower odds of receiving radiation therapy than patients who lived in the West/Hawaii region.
Utilization of Hospice Care
Of the 816 patients in our study, 254 (31.1%) had no hospice care after their metastatic melanoma diagnosis, 471 (57.7%) had short-term (1 to 3 d) hospice care, and 91 (11.1%) had long-term (Z4 d) hospice care. The use of hospice (Fig. 2) illustrated an increasing trend, from 61% in 2000 to 79% in 2007 (Cochran-Armitage trend test, P = 0.07). However, the increased enrollment was more drastic and spiked early for patients using short-term hospice care, whereas long-term hospice care use showed a steadier, more consistent increase in the enrollment rate of around 11% over 8 years.
Patients who enrolled in long-term hospice care had their first hospice admission months earlier relative to the time of death than those who used hospice for only 1 to 3 days. Among patients who used long-term hospice care, 27.5% of the users started hospice care 6 months before death, 75.9% started hospice care from 1 to 6 months before death, and only 1.1% first used hospice care in the last month before death. In contrast, 84.4% of the short-term hospice care users contacted a hospice in the last month of life for the first time.
We examined the factors associated with the use of hospice care combining all 8 years covered by the review (Table 3 ). Only 2 variables were significantly associated with a higher odds ratio for the duration of hospice care: the time of first contact with hospice and the SEER geographic region. Patients who enrolled in hospice at an early time after diagnosis were more likely (P < 0.0001) to use more days of hospice care than those entering hospice only in the last 3 months. Patients who lived in the SEER south region were more likely to receive long-term hospice care (odds ratio, 2.55; P = 0.03).
The Influence of Hospice Care on the Utilization of Chemotherapy, Surgery, and Radiation Therapy
Overall rates of chemotherapy use were similar for the long-term and the short-term hospice care groups, at 35.2% and 30.9%, respectively (Fig. 3) . The rate of chemotherapy use decreased precipitously to 5.5% in the last 3 months of life for patients in long-term hospice care, compared with 18.1% in the short-term hospice care group. In the short-term hospice group, the use of chemotherapy was 6.9% in the last month of life and 1.1% in the last week of life, which compares to the finding of no use of chemotherapy in the last month of life in the longterm hospice care group.
Patients who did not enroll in long-term hospice care showed the highest overall rate of use of surgery (25%) compared with 19.8% of those who enrolled in long-term hospice care. The difference in surgery use between these 2 groups increased when the patients entered the last 6 months of life, with respective rates at 19.6% and 4.4%. As with chemotherapy use, patients in the long-term hospice care group had no surgery use in the last month of life, whereas those who did not elect Z4 days of hospice care experienced a 3.9% rate of surgery use in the last month of life and a 0.1% rate of surgery in the last week of life.
Patients electing short-term hospice care had a 40.4% overall rate of radiation therapy, compared with 29.7% for those enrolled in long-term hospice care (P = 0.05). No longterm hospice patients received radiation therapy in the last month of life, whereas those not electing Z4 days of hospice care showed a 10.8% rate of radiation therapy use in the last month of life, and a 1.4% rate of use in the last week of life.
DISCUSSION
We observed that the use of surgery increased significantly over the study period among patients with metastatic melanoma at diagnosis, whereas the use of chemotherapy and radiation therapy fluctuated within a stable range. When we examined the influence of hospice enrollment on the utilization of cancer treatments, we found that the use of chemotherapy, surgery, and radiation therapy among patients who enrolled in Z4 days of hospice care after their diagnosis was significantly lower compared with those who did not use hospice care or who used short-term hospice care. The duration of hospice enrollment was significantly associated with how soon after diagnosis a patient elected the Medicare hospice benefit and residence in the southern SEER region. These findings suggest that early initiation of hospice care and thus longer duration of hospice care has a mitigating effect on the use of other cancer treatment modalities for patients with metastatic melanoma. A study by Emanuel et al 5 found that 33% of cancer patients underwent chemotherapy in the last 6 months of life, 23% in the last 3 months, and 9% in the last month of life in Massachusetts, and that the respective rates were similarly 26%, 20%, and 9% for cancer patients in California. They also found that the proportion of patients receiving chemotherapy was not influenced by the effectiveness of chemotherapy. 5 A study by Earle et al 6 found that 15.7% of patients received chemotherapy within 2 weeks of death, with a range of 13.8% in 1993 to 18.5% in 1996. Miesfeldt et al 14 reported that 6% of Medicare cancer patients received chemotherapy within the last 2 weeks before death. In our cohort of patients with metastatic melanoma, chemotherapy use rates were similar to those found in these previous studies. However, we observed that these utilization rates were significantly reduced if the patients enrolled in long-term hospice care.
Kwok et al, 15 studied the pattern of surgical care in the last year of life for Medicare patients. In reviewing records for >1.8 million elderly patients, they found that 31.9% of patients underwent surgery in the last year of life, 18.3% of patients underwent surgery in the last month of life, and 8.0% of patients underwent surgery in the last week of life. 15 Our study of patients with metastatic melanoma showed an overall lower rate of surgery use than their study regardless of hospice use in all observation periods.
There are no current estimates of hospice use among metastatic melanoma patients. According to a National Hospice and Palliative Care Organization report, in 2010, 41.9% of all patients who died in the United States were cared for by hospice programs. 7 After the 1989 Congressional mandate (PL 7 The hospice care duration is still mostly short-term hospice care of 1 to 3 days, even though hospice care has been found to improve quality of life. 20, 21 The demand for hospice will continue to grow along with the aging population and the escalating health care costs associated with cancer treatment. 16 Patient anxiety about surrendering access to potentially curative treatments when they elect hospice care may have contributed to the preponderance of hospice care being shortterm in nature, but the emerging concept of concurrent care, as defined in the Affordable Care Act, 22 might change this pattern of hospice care election. Concurrent care gives terminally ill patients an opportunity to have potentially curative treatment and hospice care simultaneously. 23 Traditionally, however, in order to have hospice care, patients have had to give up aggressive care, as reflected in our study by the lower utilization rates of the 3 kinds of anticancer treatments among patients who enrolled in long-term hospice care. The provision of concurrent care might prevent patients from resisting enrollment in hospice. Even though our study showed an increase in the use of hospice over the last decade, most of the increase could be attributed to enrollment in short-term hospice care. The high proportion of short-term hospice care users confirmed findings by Earle et al, 6 who suggested that most patients and physicians may use hospice care as an opportunity to process impending death. This short-term use likely restricts the palliative benefits of hospice care, 24, 25 thus compromising quality of care, and reducing patient satisfaction with care. 26, 27 Previous studies have found that the use of hospice is based on many non-patient-related factors, such as the availability of hospice rather than patients' preferences. 28, 29 Fewer hospital beds, more physicians per capita, and a higher managed health care organization enrollment are also factors associated with the high use of hospice. 17 Bergman et al 30 compared hospice use and more aggressive anticancer care use by patients dying with prostate cancer from 1992 to 2005; they found that the African American race and a higher Charlson comorbidity index score were correlated with lower hospice use and that having a partner in recent years were associated with high odds of having hospice care. Miesfeldt et al 14 found that female patients and older patients were less likely to receive aggressive care and late hospice enrollment. Lackan et al 31 studied Medicare beneficiaries and found that hospice use was significantly associated with many factors, such as the type of insurance, the age, the marital status, the race, the sex, the residence status, the type of cancer, the income level, and the education level. Variations in the use decreased over time for these subgroups because of the increased availability of hospice and changes in attitudes about death. 31 Our study found the time of first encounter with hospice was an important factor for influencing the length of hospice use.
Our study has limitations associated with retrospective analyses of claims data. The foremost limitation of our study was the impossibility to obtain data from the registry and medical claim data sets describing the preference of patients and providers regarding cancer treatments and hospice selection. Another limitation is that the population in the database is restricted to patients aged 65 years or above, and so it should be noted that these data may not reflect the patterns of care for younger patients. Also, the inability to analyze claims data for those enrolled in managed care organizations limited the sample size and the generalizability of the study findings. Moreover, recently available molecular agents such as vemurafenib and ipilimunab have shown improved outcomes in patients with metastatic melanoma and might alter the trends observed in this analysis. 32 One caveat to our study also arises in that SEER designates a patient's cancer to be metastatic if there is evidence of metastases within 6 months of diagnosis or at the end of the first course of treatment. Therefore, it is possible that some surgeries were performed on patients who were not thought to have metastatic disease. Finally, the representativeness of SEER-Medicare data sets for estimating national trends has been challenged in a recent study. 33 In conclusion, publications have focused on many other types of cancer patients, but have not examined care for patients with metastatic melanoma previously. For patients with metastatic melanoma whose potential for long-term survival is limited by the advanced nature of their disease, the quality of life for a patient's remaining time should be considered when weighing the possible benefits of surgery, chemotherapy, or radiation therapy. Continuing trends toward enrollment in hospice may further improve patient-reported outcomes such as satisfaction and improved quality of life and contribute to appropriate cost containment for patients with metastatic melanoma.
